The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Betahistine dihydrochloride 16 mg Tablets



Azure Pharmaceuticals Ltd.PA22871/017/002

Main Information

Trade NameBetahistine dihydrochloride 16 mg Tablets
Active SubstancesBetahistine dihydrochloride
Dosage FormTablet
Licence HolderAzure Pharmaceuticals Ltd.
Licence NumberPA22871/017/002

Group Information

ATC CodeN07CA01 betahistine

Status

License statusAuthorised
Licence Issued21/01/2022
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportPDF Version

Generics Information

Interchangeable ListBetahistine 16mg Tablets
Interchangeable List CodeIC0084-038-002
Interchangeable List DocumentPDF of Interchangeable List
« Back